TP53 and hematologic disorder: Small-molecule MDM2 antagonists that disrupt the interaction between p53 and MDM2 to activate the p53 pathway have shown initial signs of antitumor efficacy in patients with solid and hematologic malignancies (Andreeff et al., 2016; Ray-Coquard et al., 2012).